Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574409 | 1.00 | CTSD (0.41) | CTSDBACE1MEN1KMT2AKDM4E | |
| SCHEMBL29574775 | 0.92 | HPGD (0.43) | CTSDBACE1MEN1KMT2AMAPT | |
| SCHEMBL22925090 | 0.92 | HPGD (0.43) | CTSDBACE1MEN1KMT2AMAPT | |
| SCHEMBL16323046 | 0.92 | LMNA (0.44) | CTSDBACE1MEN1KMT2AKDM4E | |
| SCHEMBL18259637 | 0.89 | THRB (0.40) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18259519 | 0.88 | S1PR3 (0.35) | CTSDBACE1MEN1KMT2ATHRB | |
| SCHEMBL14856510 | 0.86 | DHFR (0.47) | MEN1KMT2ATHRBDHFRALDH1A1 | |
| SCHEMBL31390338 | 0.86 | DHFR (0.47) | MEN1KMT2ATHRBDHFRALDH1A1 | |
| SCHEMBL18259913 | 0.86 | PIK3CA (0.37) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18259620 | 0.85 | CHRNA7 (0.39) | CTSDBACE1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003525-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADER | Sun Pharma Advanced Research Company Ltd (IN) | 2022-06-01 | — | — | EP | disclosed |
| US-11014915-B2 | Selective estrogen receptor degrader | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-05-25 | — | — | US | disclosed |
| US-20210024504-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADER | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-01-28 | — | — | US | disclosed |
| WO-2021014386-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADER | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-01-28 | — | — | WO | disclosed |
| EP-3233818-A1 | DERIVATIVES OF 2,3-DIPHENYLCHROMENE USEFUL FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097073-A1 | DERIVATIVES OF 2,3-DIPHENYLCHROMENE USEFUL FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097073-A1 | DERIVATIVES OF 2,3-DIPHENYLCHROMENE USEFUL FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024504-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADER | ESR1, GPER1, ESR2 | CTSD 106/4885BACE1 977/4885MEN1 2741/4885 |
| US-11014915-B2 | Selective estrogen receptor degrader | ESR1, GPER1, ESR2 | CTSD 106/4885BACE1 977/4885MEN1 2741/4885 |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | CTSD 3968/4885BACE1 1306/4885MEN1 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.